^
Association details:
| Biomarker: | NPM1 mutation + NRAS mutation |
|---|---|
| Cancer: | Acute Myelogenous Leukemia |
| Drug: | Tibsovo (ivosidenib) (IDH1 inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
Complex Polyclonal Resistance Mechanisms to Ivosidenib Monotherapy in IDH1-Mutant Relapsed or Refractory Acute Myeloid Leukemia Revealed By Single Cell Sequencing Analyses
Published date:
11/06/2019
Excerpt:
Figure 2 demonstrates two distinct mIDH1 clones at baseline, one harboring NPM1/NRAS co-mutations and the other harboring NPM1/FLT3-TKD co mutations. Following IVO treatment, the IDH1/NPM1/NRAS clone was no longer detected…. Reduction in the IDH1/NPM1/FLT3-TKD clone was observed at Cycle 2 Day 1, but it ultimately expanded at relapse with the acquisition of mIDH2. In both cases, plasma 2-HG was first inhibited by >95% but increased at relapse.
DOI:
https://doi.org/10.1182/blood-2019-122703
Trial ID:
